Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval
Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...
CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...
Sisram Medical’s Alma Harmony and Alma Hybrid Receive EU Medical Device Certification
Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...
Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion
Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised...
Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through...
Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development
China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into...
GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies
China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...
YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with...
Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...
Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead
Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...
CanSino Biologics Partners with Etana for Inhaled Tuberculosis Vaccine Development
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based...
Zhida Pharma Secures Licensing Deal for Vivesto AB’s Apealea in China
Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing...
Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange
Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal
US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered...
GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324
UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...
Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC
US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with...
Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO
Cloudbreak Pharma Inc., a Cayman Island-registered ophthalmology biotech company, has filed for an initial public...